Literature DB >> 25364395

Deciding site of biopsy at metastatic relapse.

Ajit Venniyoor1.   

Abstract

Year:  2014        PMID： 25364395      PMCID： PMC4206653          DOI： 10.1177/1758834014551935

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  5 in total

1.  Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient.

Authors:  L D C Hoefnagel; P van der Groep; M J van de Vijver; J E Boers; P Wesseling; J Wesseling; E van der Wall; P J van Diest
Journal:  Ann Oncol       Date:  2013-10-10       Impact factor: 32.976

Review 2.  Tumor heterogeneity in the clinic: is it a real problem?

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

3.  When to order a biopsy to characterise a metastatic relapse in breast cancer.

Authors:  T Foukakis; G Åström; L Lindström; T Hatschek; J Bergh
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

Review 4.  Theranostic applications of antibodies in oncology.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Sandra Heskamp; Carla M L van Herpen; Wim J G Oyen; Winette T A van der Graaf; Otto C Boerman
Journal:  Mol Oncol       Date:  2014-03-21       Impact factor: 6.603

5.  First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.

Authors:  Jens Sörensen; Dan Sandberg; Mattias Sandström; Anders Wennborg; Joachim Feldwisch; Vladimir Tolmachev; Gunnar Åström; Mark Lubberink; Ulrike Garske-Román; Jörgen Carlsson; Henrik Lindman
Journal:  J Nucl Med       Date:  2014-03-24       Impact factor: 10.057
  5 in total
  1 in total

1.  Deciding site of biopsy at metastatic relapse: reply.

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.